Mozobil News and Research

RSS
New drug makes chemotherapy more effective in treating acute myeloid leukemia

New drug makes chemotherapy more effective in treating acute myeloid leukemia

Findings on cell working could lead to test and therapy for kidney failure caused by E. coli

Findings on cell working could lead to test and therapy for kidney failure caused by E. coli

Genzyme third quarter revenue increases to $1.0 billion

Genzyme third quarter revenue increases to $1.0 billion

Genzyme second-quarter revenue decreases to $1.08 billion

Genzyme second-quarter revenue decreases to $1.08 billion

Genzyme to initiate $2 billion stock buyback

Genzyme to initiate $2 billion stock buyback

Genzyme announces fourth-quarter and full-year 2009 financial results

Genzyme announces fourth-quarter and full-year 2009 financial results

Mozobil with chemotherapy may have a therapeutic impact on leukemic cells, reveals study

Mozobil with chemotherapy may have a therapeutic impact on leukemic cells, reveals study

CAM314 randomized Phase 3 clinical trial results released

CAM314 randomized Phase 3 clinical trial results released

Ascent Therapeutics demonstrates Pepducin efficacy

Ascent Therapeutics demonstrates Pepducin efficacy

Genzyme’s Mozobil approved in Europe

Genzyme’s Mozobil approved in Europe

Researchers trick bone marrow into releasing mesenchymal stem cells

Researchers trick bone marrow into releasing mesenchymal stem cells

FDA approves Mozobil (plerixafor) for multiple myeloma or non-Hodgkin's lymphomas

FDA approves Mozobil (plerixafor) for multiple myeloma or non-Hodgkin's lymphomas